HRP20020798A2 - 5-ALKYLPYRIDO[2,3-d]PYRIMIDINES TYROZINE KINASE INHIBITORS - Google Patents

5-ALKYLPYRIDO[2,3-d]PYRIMIDINES TYROZINE KINASE INHIBITORS

Info

Publication number
HRP20020798A2
HRP20020798A2 HR20020798A HRP20020798A HRP20020798A2 HR P20020798 A2 HRP20020798 A2 HR P20020798A2 HR 20020798 A HR20020798 A HR 20020798A HR P20020798 A HRP20020798 A HR P20020798A HR P20020798 A2 HRP20020798 A2 HR P20020798A2
Authority
HR
Croatia
Prior art keywords
tyrozine
alkylpyrido
pyrimidines
kinase inhibitors
kinase
Prior art date
Application number
HR20020798A
Inventor
Richard John Booth
Ellen Myra Dobrusin
Peter Laurence Toogood
Scott Norman Vanderwel
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of HRP20020798A2 publication Critical patent/HRP20020798A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HR20020798A 2000-03-06 2002-10-04 5-ALKYLPYRIDO[2,3-d]PYRIMIDINES TYROZINE KINASE INHIBITORS HRP20020798A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18712400P 2000-03-06 2000-03-06
PCT/US2001/002657 WO2001070741A1 (en) 2000-03-06 2001-01-29 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
HRP20020798A2 true HRP20020798A2 (en) 2004-02-29

Family

ID=22687699

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20020798A HRP20020798A2 (en) 2000-03-06 2002-10-04 5-ALKYLPYRIDO[2,3-d]PYRIMIDINES TYROZINE KINASE INHIBITORS

Country Status (36)

Country Link
EP (1) EP1268476A1 (en)
JP (1) JP2003528101A (en)
KR (1) KR20020075805A (en)
CN (1) CN1422268A (en)
AP (1) AP2002002643A0 (en)
AR (1) AR034119A1 (en)
AU (1) AU2001233028A1 (en)
BG (1) BG107161A (en)
BR (1) BR0109056A (en)
CA (1) CA2401368A1 (en)
CO (1) CO5280200A1 (en)
CR (1) CR6736A (en)
CZ (1) CZ20022929A3 (en)
DZ (1) DZ3308A1 (en)
EA (1) EA200200802A1 (en)
EE (1) EE200200506A (en)
GT (1) GT200100037A (en)
HN (1) HN2001000040A (en)
HR (1) HRP20020798A2 (en)
HU (1) HUP0300136A2 (en)
IL (1) IL151480A0 (en)
IS (1) IS6524A (en)
MA (1) MA26881A1 (en)
MX (1) MXPA02008535A (en)
NO (1) NO20024235L (en)
NZ (1) NZ520962A (en)
OA (1) OA12227A (en)
PA (1) PA8513201A1 (en)
PE (1) PE20011177A1 (en)
PL (1) PL358271A1 (en)
SK (1) SK12472002A3 (en)
SV (1) SV2001000338A (en)
TN (1) TNSN01036A1 (en)
WO (1) WO2001070741A1 (en)
YU (1) YU66502A (en)
ZA (1) ZA200207110B (en)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053070B2 (en) * 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
MXPA03003612A (en) 2000-10-23 2003-06-19 Smithkline Beecham Corp Novel compounds.
ATE305303T1 (en) * 2001-02-12 2005-10-15 Hoffmann La Roche 6-SUBSTITUTED PYRIDOPYRIMIDINES
JP4166991B2 (en) 2001-02-26 2008-10-15 田辺三菱製薬株式会社 Pyridopyrimidine or naphthyridine derivatives
AU2002324450A1 (en) * 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel pyridopyrimidines and uses thereof
US20030100572A1 (en) * 2001-06-21 2003-05-29 Ariad Pharmaceuticals,Inc. Novel pyridopyrimidones and uses thereof
SI1470124T1 (en) 2002-01-22 2006-04-30 Warner Lambert Co 2-(PYRIDIN-2-YLAMINO)-PYRIDO 2,3-d)PYRIMIDIN-7-ONES
AU2003225072A1 (en) 2002-04-19 2003-11-03 Smithkline Beecham Corporation Novel compounds
DE60313339T2 (en) 2002-07-31 2008-01-03 Critical Outcome Technologies, Inc. PROTEIN TYROSINE KINASE INHIBITORS
US7629347B2 (en) 2002-10-09 2009-12-08 Critical Outcome Technologies, Inc. Protein tyrosine kinase inhibitors
MXPA05007503A (en) * 2003-01-17 2005-09-21 Warner Lambert Co 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation.
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
CA2536954C (en) 2003-08-29 2012-11-27 Exelixis, Inc. C-kit modulators and methods of use
EP1685131B1 (en) 2003-11-13 2007-03-07 F. Hoffmann-La Roche AG Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
DE102004029784A1 (en) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel 2-Benzylaminodihydropteridinones, process for their preparation and their use as medicaments
DE102004033670A1 (en) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg New pyridodihydropyrazinone, process for its preparation and its use as a medicament
FR2873118B1 (en) 2004-07-15 2007-11-23 Sanofi Synthelabo PYRIDO-PYRIMIDINE DERIVATIVES, THEIR APPLICATION IN THERAPEUTICS
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
EP1630163A1 (en) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinones, methods for their preparation and their use as drugs
CA2575804A1 (en) * 2004-08-26 2006-03-02 Boehringer Ingelheim International Gmbh Pteridinones used as plk (polo like kinase) inhibitors
DE102004058337A1 (en) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for the preparation of fused piperazin-2-one derivatives
JP2008527007A (en) 2005-01-14 2008-07-24 ミレニアム・ファーマシューティカルズ・インコーポレイテッド Cinnamide and hydrocinnamide derivatives having Raf-kinase inhibitory activity
JP2008535822A (en) 2005-03-25 2008-09-04 グラクソ グループ リミテッド New compounds
TW200724142A (en) 2005-03-25 2007-07-01 Glaxo Group Ltd Novel compounds
TWI389690B (en) 2005-03-25 2013-03-21 Glaxo Group Ltd Novel compounds
KR20080002865A (en) 2005-03-25 2008-01-04 글락소 그룹 리미티드 Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1h)-one derivatives
US7737155B2 (en) * 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
FR2887882B1 (en) 2005-07-01 2007-09-07 Sanofi Aventis Sa PYRIDO [2,3-D] PYRIMIDINE DERIVATIVES, THEIR PREPARATION, THEIR THERAPEUTIC APPLICATION
US7642270B2 (en) 2005-09-14 2010-01-05 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase
TW200800983A (en) 2005-09-14 2008-01-01 Janssen Pharmaceutica Nv 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
EA016945B1 (en) * 2005-10-07 2012-08-30 Экселиксис, Инк. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα
US8247408B2 (en) * 2005-10-07 2012-08-21 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer
FR2896246B1 (en) 2006-01-13 2008-08-15 Sanofi Aventis Sa PYRIDO-PYRIMIDONE DERIVATIVES, THEIR PREPARATION, THEIR THERAPEUTIC APPLICATION
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
SI2074122T1 (en) 2006-09-15 2011-10-28 Pfizer Prod Inc Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors
JP2010506902A (en) * 2006-10-16 2010-03-04 ジーピーシー・バイオテック・インコーポレーテッド Pyrido [2,3-D] pyrimidines and their use as kinase inhibitors
EP1914234A1 (en) * 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
WO2008055013A2 (en) * 2006-10-31 2008-05-08 Janssen Pharmaceutica N.V. 5-oxo-5,8 - dihydro - pyrido - pyrimidines as inhibitors of c-fms kinase
FR2910813B1 (en) 2006-12-28 2009-02-06 Sanofi Aventis Sa NEW THERAPEUTIC USE FOR THE TREATMENT OF LEUKEMIA
AU2008237507B2 (en) * 2007-04-03 2014-03-20 Array Biopharma Inc. Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
AU2008262837B2 (en) * 2007-06-15 2013-05-23 Msd K.K. Bicycloaniline derivative
EP2185559A1 (en) 2007-08-03 2010-05-19 Boehringer Ingelheim International GmbH Crystalline form of a dihydropteridione derivative
AU2008343932B2 (en) 2007-12-19 2013-08-15 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
WO2009079797A1 (en) 2007-12-26 2009-07-02 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
EP2100894A1 (en) * 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
MX2010010975A (en) 2008-04-07 2010-11-01 Amgen Inc Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors.
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
CA2999321A1 (en) 2008-07-17 2010-01-21 Critical Outcome Technologies Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
PA8843901A1 (en) 2008-09-30 2010-05-26 PI3K PYRIMIDINONE INHIBITORS (ALFA) AND m TOR
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
JP2013507395A (en) * 2009-10-09 2013-03-04 アフラクシス・インコーポレイテッド 8-Ethyl-6- (aryl) pyrido [2,3-D] pyrimidin-7 (8H) -one for the treatment of CNS disorders
US8889696B2 (en) 2009-12-18 2014-11-18 Temple University—Of the Commonwealth System of Higher Education Substituted pyrido[2,3-d]pyrimidin-7(8H)-ones and therapeutic uses thereof
WO2011100319A1 (en) 2010-02-09 2011-08-18 Exelixis, Inc. Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k and mtor in combination with autophagy inhibitors
US8987272B2 (en) 2010-04-01 2015-03-24 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV
US8987267B2 (en) 2010-08-05 2015-03-24 Temple University—Of the Commonwealth System of Higher Education 2-substituted-8-alkyl-7-OXO-7,8-dihydropyrido[2,3-D]pyrimidine-6-carbonitriles and uses thereof in treating proliferative disorders
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
JP6000273B2 (en) 2010-11-29 2016-09-28 オーエスアイ・ファーマシューティカルズ，エルエルシー Macrocyclic kinase inhibitor
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
KR101606250B1 (en) 2011-03-23 2016-03-24 암젠 인크 Fused tricyclic dual inhibitors of cdk 4/6 and flt3
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
KR102027598B1 (en) * 2011-05-17 2019-10-01 프린시피아 바이오파마, 인코퍼레이티드 Tyrosine kinase inhibitors
MX2014010176A (en) * 2012-02-23 2014-11-10 Abbvie Inc Pyridopyrimidinone inhibitors of kinases.
SI2958916T1 (en) * 2013-02-21 2018-11-30 Pfizer Inc. Solid forms of a selective cdk4/6 inhibitor
EP3024464A1 (en) 2013-07-26 2016-06-01 Boehringer Ingelheim International GmbH Treatment of myelodysplastic syndrome
CA2954189A1 (en) 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
TWI646094B (en) * 2016-06-01 2019-01-01 大陸商貝達藥業股份有限公司 Crystal form of inhibitory protein kinase active compound and application thereof
TN2019000039A1 (en) 2016-08-15 2020-07-15 Pfizer Pyridopyrimdinone cdk2/4/6 inhibitors
WO2018160076A1 (en) * 2017-03-03 2018-09-07 Auckland Uniservices Limited Fgfr kinase inhibitors and pharmaceutical uses
EP3752491A4 (en) 2018-02-15 2021-12-01 Nuvation Bio Inc. Heterocyclic compounds as kinase inhibitors
TW202035406A (en) * 2018-12-07 2020-10-01 大陸商杭州英創醫藥科技有限公司 Heterocyclic compound as CDK-HDAC dual pathway inhibitor
CN112759589B (en) * 2019-11-01 2022-04-08 暨南大学 Pyrimidopyridinones and their use
US11697648B2 (en) 2019-11-26 2023-07-11 Theravance Biopharma R&D Ip, Llc Fused pyrimidine pyridinone compounds as JAK inhibitors
WO2022188755A1 (en) * 2021-03-08 2022-09-15 暨南大学 Pyridopyrimidine-based compound and application thereof
WO2024056091A1 (en) * 2022-09-16 2024-03-21 华东师范大学 Pyridonopyrimidine derivative as rsk inhibitor and use thereof
WO2024099403A1 (en) * 2022-11-10 2024-05-16 北京普祺医药科技股份有限公司 Thioether compound having soft drug property and use thereof, and pharmaceutical composition and use thereof
WO2024107730A1 (en) * 2022-11-14 2024-05-23 Onconova Therapeutics, Inc. Methods and compositions for treating cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
JP2001509805A (en) * 1997-02-05 2001-07-24 ワーナー−ランバート・コンパニー Pyrido [2,3-D] pyrimidine and 4-aminopyrimidine as cell growth inhibitors
NZ508268A (en) * 1998-05-26 2004-02-27 Warner Lambert Co Bicyclic pyrimidines and bicyclic 3,4- dihydropyrimidines as inhibitors of cellular proliferation

Also Published As

Publication number Publication date
KR20020075805A (en) 2002-10-05
EE200200506A (en) 2004-02-16
IS6524A (en) 2002-08-23
CZ20022929A3 (en) 2003-02-12
SK12472002A3 (en) 2003-04-01
BG107161A (en) 2003-06-30
GT200100037A (en) 2002-03-04
MXPA02008535A (en) 2002-12-13
DZ3308A1 (en) 2001-09-27
NO20024235L (en) 2002-11-05
TNSN01036A1 (en) 2005-11-10
AU2001233028A1 (en) 2001-10-03
EA200200802A1 (en) 2003-02-27
OA12227A (en) 2004-03-18
ZA200207110B (en) 2003-12-04
CN1422268A (en) 2003-06-04
SV2001000338A (en) 2001-11-30
HN2001000040A (en) 2001-09-06
PA8513201A1 (en) 2003-06-30
YU66502A (en) 2005-09-19
BR0109056A (en) 2003-06-03
IL151480A0 (en) 2003-04-10
CR6736A (en) 2004-03-10
JP2003528101A (en) 2003-09-24
HUP0300136A2 (en) 2003-05-28
NO20024235D0 (en) 2002-09-05
PE20011177A1 (en) 2001-11-23
CO5280200A1 (en) 2003-05-30
MA26881A1 (en) 2004-12-20
AP2002002643A0 (en) 2002-12-31
PL358271A1 (en) 2004-08-09
EP1268476A1 (en) 2003-01-02
WO2001070741A1 (en) 2001-09-27
CA2401368A1 (en) 2001-09-27
AR034119A1 (en) 2004-02-04
NZ520962A (en) 2003-09-26

Similar Documents

Publication Publication Date Title
HRP20020798A2 (en) 5-ALKYLPYRIDO[2,3-d]PYRIMIDINES TYROZINE KINASE INHIBITORS
IL159832A0 (en) 4-amino-6-phenyl-pyrrolo[2,3-d] pyrimidine derivatives
IL150545A0 (en) PYRIDO [2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS
IL151104A0 (en) Kinase inhibitors
AU6931701A (en) Pyrimidine derivatives
AU2001237041A1 (en) Kinase inhibitors
HK1062300A1 (en) 4-Amino-5-phenyl-7-cyclobutyl-pyrrolo (2,3-d)pyrimidine derivatives
AU3576801A (en) Pyrimidine compounds
HUP0202713A3 (en) Pteridinones as kinase inhibitors
IS2173B (en) Pyrrolo [2,3-d] pyrimidine compounds that inhibit protein kinase
AU1041802A (en) Tetrahydro-heterocycloazepinyl pyrimidine derivatives
HK1078079A1 (en) Pyrimidine derivatives
EP1259236A4 (en) Tyrosine kinase inhibitors
PL358551A1 (en) 5-aminoalkyl-pyrazolo[4,3-d]pyrimidines
MXPA03004498A (en) Use of pyrazolo[4,3-d]pyrimidines.
MXPA03000504A (en) Pyrimidine derivatives.
MXPA03004907A (en) Use of pyrazolo[4,3-d]pyrimidines.
AU8578501A (en) 2-aminoalkyl-thieno(2,3-d)pyrimidines
AU2001285785A1 (en) 2-aminoalkyl-thieno[2,3-d]pyrimidines
IL155380A0 (en) SUBSTITUTED 3,4-DIHYDRO-PYRIDO[1,2-a] PYRIMIDINES
SI1303496T1 (en) Pyrimidine derivatives
GB0130695D0 (en) Pyrazola[4,3]pyrimidine

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
OBST Application withdrawn